 |
Video: What is a Stock Split?
|
 |
Aardvark Therapeutics is a clinical-stage biopharmaceutical focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for treating metabolic diseases. Co. focused on developing Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Initial compounds target TAS2Rs expressed in the gut lumen, which normally respond to the nutrients in food and participate in the gut-brain axis. Co. lead product candidate, ARD-101 (denatonium acetate monohydrate), is an oral gut-restricted small-molecule agonist of certain TAS2Rs for which Co. initiated a Phase 3 clinical trial for hyperphagia associated with Prader-Willi Syndrome (PWS). According to our AARD split history records, Aardvark Therapeutics has had 1 split. | |
 |

Aardvark Therapeutics (AARD) has 1 split in our AARD split history database. The split for AARD took place on July 21, 2008. This was a 1 for 2 reverse split, meaning for each 2 shares of AARD owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 500 share position following the split.
When a company such as Aardvark Therapeutics conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the AARD split history from start to finish, an original position size of 1000 shares would have turned into 500 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Aardvark Therapeutics shares, starting with a $10,000 purchase of AARD, presented on a split-history-adjusted basis factoring in the complete AARD split history.

Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
02/14/2025 |
|
End date: |
07/18/2025 |
|
Start price/share: |
$13.30 |
|
End price/share: |
$11.62 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-12.63% |
|
Annualized Gain: |
-30.13% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$8,737.00 |
|
Years: |
0.42 |
|
|
 |
Date |
Ratio |
07/21/2008 | 1 for 2 |
|
 |